Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Feb 24, 2023 2:29pm
51 Views
Post# 35304030

RE:Midatech Share Price Is Dropping

RE:Midatech Share Price Is Dropping"Midatech's share price has been dropping from 76.5¢ on February 9th, the day that Midatech announced its new financing at an initial proice of 58¢ per unit. As I write this, the Midatech share price is down 33% to 50.8¢."

The S&P Biotech ETF began dropping around the same time. Since Feb 2 it is down about 11.2%. That's a big drop for an index with advanced companies. Preclinical is a real hell hole during an inflation scare. xB3 may be 2 years from the clinic and a proof in humans let alone revenue. That's why Rathjen has tried to add Phase II ready assets like Cresence and when that wasn't enough Biodexa. Biodexa would have had enough cash to get to hard data with the Armistice financing. Midatech needs to produce a proof in humans for glioblastoma and get closer to revenue.  
<< Previous
Bullboard Posts
Next >>